Enhancing The Immune System To Recognise & Attack Cancer Cells
What Is Personalised Cancer Immunotherapy ?
Immunotherapy is a new class of cancer treatment that works to harness the innate powers of the immune system to fight cancer. Because of the immune system's unique properties, these therapies may hold greater potential than current treatment approaches to fight cancer, to offer longer-term protection against the disease with comparatively minimum side effects.
Detects and attacks cancer cells through out the body
Trains the immune system to target cancer cells only
Capacity of memory means durability of protection
The treatment technology can be used for the treatment of other types of cancers as well
Immunotherapy is customised using the patient’s own tumour tissue & monocytes which reduces the chances of side-effects.
APAC Biotech's Therapeutic Platform
The potential to harness the potency and specificity of the immune system underlies the growing interest in cancer immunotherapy. One such approach uses bone marrow–derived dendritic cells, phenotypically distinct and extremely potent antigen-presenting cells, to present tumor-associated antigens and thereby generate tumor-specific immunity.
Support for this strategy comes from animal studies that have demonstrated that dendritic cells, when loaded ex vivo with tumour antigens and administered to tumour-bearing hosts, can elicit T cell–mediated tumour destruction. These observations have led to clinical trials designed to investigate the immunologic and clinical effects of antigen-loaded dendritic cells administered as a therapeutic vaccine to patients with cancer. In the design of this personalised therapy, important considerations include antigen selection, methods for introducing the antigen into MHC class I and II processing pathways, methods for isolating and activating dendritic cells, and route of administration needs to be considered.
Promising results from clinical trials in patients with various malignancies suggest that immunotherapeutic strategies that take advantage of the antigen presenting properties of dendritic cells may ultimately prove both efficacious and widely applicable to human tumours.